Share on StockTwits

Aratana Therapeutics (NASDAQ:PETX) issued its quarterly earnings data on Tuesday. The company reported ($0.32) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.36) by $0.04, American Banking News reports.

PETX has been the subject of a number of recent research reports. Analysts at Jefferies Group reiterated a “buy” rating on shares of Aratana Therapeutics in a research note on Friday, June 6th. They now have a $23.00 price target on the stock, down previously from $25.00. Analysts at Stifel Nicolaus reiterated a “buy” rating on shares of Aratana Therapeutics in a research note on Wednesday, May 14th. They now have a $22.00 price target on the stock, down previously from $30.00. Four research analysts have rated the stock with a buy rating, Aratana Therapeutics has an average rating of “Buy” and an average price target of $30.40.

Aratana Therapeutics (NASDAQ:PETX) opened at 10.40 on Tuesday. Aratana Therapeutics has a 52 week low of $8.07 and a 52 week high of $29.32. The stock has a 50-day moving average of $13.65 and a 200-day moving average of $16.07. The company’s market cap is $299.1 million.

Aratana Therapeutics, Inc is a development-stage biopharmaceutical company. As of March 20, 2013, the Company has three licensed compounds in development for six product approvals in cats and dogs in each of the United States and Europe.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.